Kyverna Therapeutics (KYTX) EBITDA (2023 - 2026)

Kyverna Therapeutics (KYTX) has 4 years of EBITDA data on file, last reported at -$41.4 million in Q1 2026.

• Quarterly EBITDA rose 12.74% year-over-year to -$41.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$163.8 million (down 1.95% YoY) and the FY2025 annual result came in at -$169.8 million, down 19.09% from the prior year.
• EBITDA slipped to -$41.4 million in Q1 2026, from -$39.3 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$11.4 million in Q1 2023 to a low of -$47.4 million in Q1 2025.
• A 4-year average of -$32.0 million and a median of -$38.7 million in 2025 frame the typical range for EBITDA.
• Annual changes were most pronounced in 2024 — EBITDA slumped 156.51% — and 2026, when it grew 12.74%.
• Tracing KYTX's EBITDA over 4 years: stood at -$21.4 million in 2023, then tumbled by 91.99% to -$41.0 million in 2024, then climbed by 4.29% to -$39.3 million in 2025, then dropped by 5.31% to -$41.4 million in 2026.
• The last three EBITDA figures came in at -$41.4 million (Q1 2026), -$39.3 million (Q4 2025), and -$38.7 million (Q3 2025), per Business Quant data.